TCR Engineered Donor T-Cells
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 75 patients (estimated)
- Sponsors
- TScan Therapeutics, Inc.
- Tags
- Adoptive Cellular Therapy, T Cell (Allogeneic), Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1606
- NCT Identifier
- NCT05473910
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.